Merrimack and Baxalta snag FDA fast-track promise; Teva moves forward with long-delayed MS drug;

@FierceBiotech: ICYMI yesterday: Little NeuroRx boasts big about a new ketamine combo for bipolar depression. Article | Follow @FierceBiotech

@JohnCFierce: Isn't it strange that biotech is booming and R&D jobs have never been so uncertain? | Follow @JohnCFierce

> Teva ($TEVA) and partner Active Biotech have wrapped up enrollment in a Phase III trial on the long-delayed multiple sclerosis drug laquinimod, expecting to post final results in 2017 and finally complete an FDA submission thereafter. More

> Merrimack Pharmaceuticals ($MACK) and Baxter's ($BAX) Baxalta picked up the FDA's priority-review designation for their MM-398, an in-development treatment for pancreatic cancer. The agency has promised to hand down a final decision on the drug by Oct. 24. News

> Egalet's ($EGLT) abuse-deterrent oral morphine candidate demonstrated bioequivalence to MS Contin, Purdue Pharma's top-selling morphine. Item

Medical Device News

@FierceMedDev: Google and the Broad Institute join forces for genomic data sharing. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Chris Viehbacher explains: "If I had $2 billion to invest…" More from FierceBiotech | Follow @VarunSaxena2

@EmilyWFierce: Enthusiasm could be outpacing the evidence when it comes to genetic testing, experts say. More from the NYT | Follow @EmilyWFierce

> Zimmer Biomet is born after knee implant divestiture to S&N. More

> FDA panel slated to weigh Bayer Essure safety after more than 5,000 complaints. Story

> Covidien settles the score in more than 11,000 vaginal mesh cases. Report

Pharma News

@FiercePharma: HIV vaccine research a 'major advance,' NIH official says. FierceVaccines story | Follow @FiercePharma

@EricPFierce: See which companies had the most Class I recalls in recent years. Feature from FiercePharmaManufacturing | Follow @EricPFierce

> Eli Lilly faces August trials in suits over Cymbalta withdrawal symptoms. Story

> CDC panel disappoints Pfizer, GSK with limited backing for meningitis B shots. Article

> Allergan CEO: 'The cuts are done' at layoffs-plagued Irvine campus. More

Vaccines News

> Vical posts herpes vaccine PhI/II failure, gutting shares. News

> MERS getting more attention as vaccine candidate enters PhI. More

> ACIP gives Glaxo, Pfizer a lukewarm decision for new meningitis B vaccines. Story

> NIH grants Northeastern prof $1.4M to address 'bottleneck' in vaccine development. Article

> Pfizer to acquire GlaxoSmithKline meningitis vaccines for $130M. Report

CRO News

> PRA debuts a sweeping clinical trial operating system. More

> Novasep bets $11M on armed antibody R&D. Item

> Huntingdon and Harlan move forward under a new monicker. Article

> Icon rolls out some new patient-consent tech with a focus on education. Story

> Parexel cutting 850 jobs as it dims its revenue outlook. Report

Pharma Asia News

> S. Korea sees extra $9B in spending to handle MERS outbreak. Report

> Australia's Benitec heading for Nasdaq IPO. More

> Ascletis plans China, Taiwan PhIII trials on chronic hep C therapies. Story

> CRO M&A ticks up in India, fueling hopes of turnaround. Article

> South Korea biopharma IPOs highlight demand. Item

Pharma Manufacturing News

> Novasep building ADC manufacturing plant at Le Mans site. News

> Pharmacies want more time to comply with track-and-trace rules. Item

> TxCell halts drug production, a decision made with French regulator. Report

> FDA slaps U.S. drugmaker over drug testing issues. Story

> Hospira finally up and running at its cost-cutting India plant. Article

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.